Advanced Targeting Systems

Executive Summary

Advanced Targeting Systems (ATS) is a San Diego-based biotechnology company that specializes in targeted research reagents, most notably its proprietary saporin-based conjugates used for 'Molecular Surgery'—a technique to selectively eliminate specific cell types. Founded in 1994, ATS has established a strong niche in the neuroscience and antibody markets, offering products such as ZAP kits and pHast Conjugates that enable precise cell ablation in research and drug development. The company's reagents are widely used to study system functions, diseases, and disorders, making it a key supplier to academic and pharmaceutical labs. While ATS operates in a specialized segment, its long history and unique technology provide a stable revenue base and opportunities for growth through product line expansion and strategic partnerships. The company remains privately held and has not disclosed funding or valuation, suggesting a bootstrapped or steady-state business model. Looking ahead, ATS is well-positioned to leverage increasing demand for targeted cell manipulation tools in neuroscience and oncology research. However, its limited size and lack of public information temper the conviction in its growth trajectory. Overall, ATS represents a niche player with proven technology and potential for incremental expansion.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation saporin conjugates for oncology research60% success
• Q4 2026Partnership with a major pharmaceutical company for targeted toxin delivery40% success
• Q3 2026Expansion of product line into neurological disease models70% success